The BBB is now thought of as a biological rather than an insurmountable barrier, as proven by the successful laboratory and clinical tests with tofersen (SOD1-ALS), LNP-mRNA progranulin restoration, and focused-ultrasound-facilitated antibody therapy [25,48,92]. This evidence concerns the gene SOD1 and amyotrophic lateral sclerosis.